| 研究課題/領域番号 |
22K14548
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分27040:バイオ機能応用およびバイオプロセス工学関連
|
|---|
| 研究機関 | 立命館大学 |
|---|
研究代表者 |
ABDALKADER Rodi 立命館大学, 立命館グローバル・イノベーション研究機構, 助教 (20839964)
|
|---|
| 研究期間 (年度) |
2022-04-01 – 2024-03-31
|
| 研究課題ステータス |
交付 (2022年度)
|
| 配分額 *注記 |
4,550千円 (直接経費: 3,500千円、間接経費: 1,050千円)
2023年度: 2,340千円 (直接経費: 1,800千円、間接経費: 540千円)
2022年度: 2,210千円 (直接経費: 1,700千円、間接経費: 510千円)
|
|---|
| キーワード | Cornea-on-a-chip / Microfluidic / Metabolomic / Drug toxicity / cornea-on-a-chip / iPSC / metabolomics |
|---|
| 研究開始時の研究の概要 |
This proposal aims for the development of a dynamic human cornea model in integration with untargeted metabolomics by combining human induced pluripotent stem cells (iPSC), microfluidics technologies, and metabolomics. This approach will allow us to investigate the early toxicity of the ophthalmic drugs through the selection of significant metabolites markers upon drugs exposure.
|
| 研究実績の概要 |
This research aims to identify metabolite markers related to drug toxicity using untargeted metabolomic analysis in a human corneal epithelium-on-a-chip. In the current fiscal year, an untargeted metabolic workflow that we previously developed was utilized to analyze extracellular metabolites in human induced pluripotent stem cells (hiPSCs) under early differentiation conditions. A total of 117 metabolites were successfully annotated in a small sample volume of one microliter. This optimized untargeted metabolomic method will be applied to the human corneal epithelium-on-a-chip in the next phase of the study.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
1: 当初の計画以上に進展している
理由
The progress of this research can be attributed to the successful optimization of the untargeted metabolomic method for detecting extracellular metabolites in both corneal epithelial cells and hiPSCs. Additionally, the establishment of functional corneal epithelial cells from hiPSCs will further facilitate the investigation of drug toxicity in the corneal epithelium-on-a-chip model with greater precision and accuracy.
|
| 今後の研究の推進方策 |
To investigate changes in extracellular metabolites, the untargeted metabolomic method optimized in the previous stage will be applied in the human corneal epithelium-on-a-chip under drug treatment.
In parallel, changes in gene expression under drug treatment will also be investigated. This will be done using transcriptomic analysis to identify differentially expressed genes in response to drug treatment.
Finally, to validate the relationship between changes in extracellular metabolites and gene expression, correlation analysis will be performed to identify any significant associations between the two. These results will provide a more comprehensive understanding of drug toxicity related metabolite markers and their underlying mechanisms.
|
